| In millions, except per share items | Jun-30-22 | Jun-30-21 | Jun-30-20 | Jun-30-19 | Jun-05-19 | Jun-30-18 |
| | 10-K | 10-K | 10-K | 10-K/A | 8-K | 10-K |
| REVENUE: | | | | | | |
| Total revenue | 764.0 | 930.0 | 529.3 | 337.5 | 337.5 | 233.7 |
| Total revenue growth | -17.8% | 75.7% | 56.9% | 44.4% | | |
| OPERATING COSTS AND EXPENSES: | | | | | | |
| Cost of revenue | 466.8 | 270.7 | 167.4 | 104.4 | 104.4 | 96.0 |
| |
| Cost of goods sold—pharmacy revenue | | | | | | |
| Marketing and advertising | 484.1 | 385.3 | 184.2 | 110.3 | 110.3 | 82.1 |
| Technical development | 24.7 | 18.6 | 12.3 | 8.3 | | 9.9 |
| Total operating costs and expenses | 2,601.2 | 1,718.1 | 944.0 | 810.0 | 241.2 | 654.1 |
| INCOME (LOSS) FROM OPERATIONS | -346.0 | 192.2 | 130.2 | 96.3 | 96.3 | 43.2 |
| Operating margin | -45.3% | 20.7% | 24.6% | 28.5% | 28.5% | 18.5% |
| INTEREST EXPENSE, NET | -43.6 | -29.3 | -24.6 | -1.7 | -1.7 | -0.9 |
| OTHER INCOME (EXPENSE), NET | 0.2 | 1.6 | 0.4 | 0.0 | 0.0 | 0.7 |
| INCOME (LOSS) BEFORE INCOME TAX EXPENSE (BENEFIT) | -389.8 | 158.0 | 104.0 | | | |
| INCOME TAX EXPENSE (BENEFIT) | -92.3 | 33.2 | 24.5 | 22.0 | 22.0 | 6.6 |
| NET INCOME (LOSS) | -297.5 | 124.9 | 79.5 | 72.6 | 72.6 | 34.9 |
| |
| NET INCOME (LOSS) PER SHARE: | | | | | | |
| Basic (in dollars per share) | ($1.81) | $0.77 | ($0.18) | $0.70 | $0.70 | $0.27 |
| Diluted (in dollars per share) | ($1.81) | $0.75 | ($0.18) | $0.55 | $0.55 | $0.23 |
| |
| WEIGHTED-AVERAGE COMMON STOCK OUTSTANDING USED IN PER SHARE AMOUNTS: | | | | | | |
| Basic (in shares) | 164.0 | 162.9 | 0.1 | 85.4 | 85.4 | 81.3 |
| Diluted (in shares) | 164.0 | 165.5 | 0.1 | 132.5 | 132.5 | 96.4 |
| |
| OTHER COMPREHENSIVE INCOME (LOSS) NET OF TAX: | | | | | | |
| Gain (loss) on cash flow hedge | 11.5 | 1.5 | -1.3 | | | |
| OTHER COMPREHENSIVE INCOME (LOSS) | 11.5 | 1.5 | -1.3 | | | |
| COMPREHENSIVE INCOME (LOSS) | -286.0 | 126.3 | 78.2 | 72.6 | 72.6 | 34.9 |